$50MSeries A, 7 January 2026
Launch financing to advance PHB-050 through Phase 1, with data expected in 2H26.
- Amount
- $50M
- Stage
- Series A
- Announced
- 7 January 2026
- Lead
- SR One
- Other investors
- Vida Ventures, Platanus
- Use of funds
- Launch financing to advance PHB-050 through Phase 1, with data expected in 2H26.
- Checked
- Announced by the company
- Sources
- Poplar Therapeutics launches with $50M Series A for anti-IgE therapy businesswire.com
Poplar Therapeutics launches with $50M Series A for anti-IgE therapy pulse2.com